Individuals with HIV who were resistant to all four antiretroviral drug classes experienced higher mortality than those who were not resistant, a difference primarily due to lower CD4 cell counts.
There’s been a lot of grim news lately about HIV and AIDS: Rising infections among high-risk U.S. communities, continued risk behaviors, and plague-level infection rates across sub-Saharan Africa. In ...
Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical ...
For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
Can we eliminate the HIV epidemic? It's a question that dates back to the start of the epidemic in the 1980s. With 1.3 million new infections a year, the epidemic continues … and the world is not on ...
Can we eliminate the HIV epidemic? It’s a question that dates back to the start of the epidemic in the 1980s. With 1.3 million new infections a year, the epidemic continues … and the world is not on ...